SCHEMBL3918834

SCHEMBL3918834

CON(C(=O)C1=C(C(=O)O)CCC1)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 10/20 0.41
SLC6A3 Q01959 2/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
F2 P00734 1/20 0.37
PKM P14618 1/20 0.37
FABP4 P15090 2/20 0.36
FABP5 Q01469 2/20 0.36
NR4A2 P43354 1/20 0.36
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 2/20 0.35
ALDH1A1 P00352 1/20 0.35
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3916870 0.84 F2 (0.40) DHODHSLC6A3SLC6A2SLC6A4F2
SCHEMBL3924649 0.79 POLB (0.47) DHODHPKMFABP4FABP5KDM4E
SCHEMBL6754119 0.76 DHODH (0.46) DHODHSLC6A3SLC6A2SLC6A4F2
SCHEMBL3914255 0.76 TSHR (0.43) DHODHHPGDTSHRALDH1A1
SCHEMBL6756240 0.76 DHODH (0.48) DHODHSLC6A3SLC6A2SLC6A4NR4A2
SCHEMBL4526462 0.74 HPGD (0.50) KDM4EHPGDTSHRALDH1A1
SCHEMBL9505872 0.74 KMT2A (0.46) KDM4EHPGDTSHRALDH1A1GLA
SCHEMBL6813884 0.74 DHODH (0.46) DHODHSLC6A3SLC6A2SLC6A4FABP4
SCHEMBL3926147 0.73 RXFP1 (0.45) DHODHTSHR
SCHEMBL5933060 0.72 NPSR1 (0.41) KDM4EHPGDTSHRALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2093214-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4SC AG (DE) 2009-08-26 EP disclosed
US-7423057-B2 Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4SC AG (DE) 2008-09-09 US disclosed
US-7176241-B2 Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4SC AG (DE) 2007-02-13 US disclosed
US-20060199856-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4 SC AG (DE) 2006-09-07 US disclosed
EP-1392642-A2 NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS 4SC AG (DE) 2004-03-03 EP disclosed
US-20030203951-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents 4SC AG (DE) 2003-10-30 US disclosed
WO-2003006425-A2 NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS 4SC AG (DE) 2003-01-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203951-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents DHODH, DLD, GCDH DHODH 1/4885SLC6A3 3904/4885SLC6A2 4705/4885
US-20060199856-A1 Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents DHODH, DLD, HADHA DHODH 1/4885SLC6A3 4025/4885SLC6A2 4776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.